---

Aim and Background: By expanding knowledge about this disease, many progress and developments for curing this disease have been performed. The toxic effects of chemotherapy drugs still pose a treatment problem, because of their pharmokinetic changes and careful targeting as one of the promising strategies are proposed in cancer and incurable disease treatments. Magnetic Nano particles are essential and vital in drug delivery, since their natural magnet, facilitates targeting and other things.

Materials and Methods: Magnetic nanoparticles were prepared by co-precipitation method. Then, by using discharge metod, liposomal nanoparticle’s film and magnetic nanoparticle’s film, containing paclitaxel were prepared. Also drug releasing and capsulation amount and drug loading, size and potential zeta of magnetized liposomal Nanoparticles were mentioned. The cytotoxicity of nanoparticles containing the drug was studied by using MTT assay on cell of ovarian cancer A2780CP.

 Conclusion:. The size of magnetic liposome nanoparticles containing the drug and the liposomes containing the drug, respectively, 251 and 198 nm were estimated. And zeta potential of these particles, respectively, -20 and -19 (mv) was calculated.   Also the magnetic liposome carrier had slow-release and longer half-life than liposome.

Encapsulation efficiency of carriers, magnetic liposome and liposome of paclitaxel respectively 97and
96 percent were. Release studies show, Continuous and controlled drug release from the magnetic liposome nanoparticles. MTT results showed that, magnetic liposome had a higher cytotoxicity than liposomal nanoparticles against cells A2780CP imposed.

Result: The results of the study showed that, magnetic liposome nanoparticles were more appropriate carrier than liposome nanoparticles for drug delivery of paclitaxel in ovarian cancer cells are A2780CP.

---

Aim & Background: Cancer is a major cause of mortality in the world. Treatment of Cancer through drug therapy/chemotherapy faces the challenges of drug delivery. Drug delivery systems such as niosomes provided high efficiency and targeted treatment. The aim of this study was to prepare a new formula of niosomal nano system containing doxorubicin as the cancer therapy drug. Changing the tissue distribution of drug leads to drug effect improvement and reducing its cytotoxicity.
 
Materials & Methods: Doxorubicin encapsulated niosomes were synthesized using thin-film method. A certain amount of Span-60 and Cholesterol dissolved by chloroform in a round bottom balloon. Rotary evaporator was used in order to remove the organic solvent and form the thin-film. The thin-film was hydrated by doxorubicin and PBS solution using rotary evaporator in 10°C higher than span-60 transition phase. Entrapment Efficiency and release profile were investigated using dialysis and spectrophotometry. Size reduction was applied by probe sonicating. Nanoparticles average diameter and zeta potentiol was measured using DLS technique and Zeta sizer. The optimum formula was PEGylated and its cytotoxicity investigated through MTT assay on Ovarian cancer cell line and fibroblast normal cells.
 
Results: The diameter of optimized and PEGylated niosomal formulation was 172.5 nm and entrapment efficiency of PEGylated doxorubicin system was about 95.83±1.18. release studies result in PBS buffer at 37°C was the sign of PEGylated nanoniosomes efficiency in controlling the drug release, which the release percent of drug after 48 hours was 20.52 and its cytotoxicity was higher than the free drug.
 
Conclusion: The study demonstrates using of drug delivery carriers such as synthesized nano-niosomes has an effective role in increasing the efficacy and reducing the consumed dosages of drug.